The University of California, at Irvine
This article was originally published in Start Up
Since 1990, UCI grew from 109th to 46th in industry-funded research. David Schetter, Director, Office of Technology Alliances believes it will crack the top 30 this year. The life sciences dominate UCI's research base.
You may also be interested in...
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.